ADC specialist Solve raises $120m, and other biofinancings Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.

#SolveTherapeutics has completed a $120 million unlabelled round as it advances a pair of antibody-drug conjugates (#ADCs) for #cancer that use its proprietary #linkertechnology.

pharmaphorum.com/news/adc-spe...